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Primary hyperparathyroidism (PHTP) is characterized by overproduction of 
parathyroid hormone and an increase in the level of serum ionized calcium. The most 
common cause of excess hormone production is the development of a benign tumor 
(adenoma) in one of the parathyroid glands.Adenoma accounts for 80-90% percent of 
all patients with PHTP.  Muscular fatigue, constipation ,weakness, lethargy, 
neuropsychiatric, neuromuscular and cardiovascular manifestations, renal stones, 
osteoporosis, ostopenia, peptic ulcers, pancreatitis and gallstones are some of the 
symptoms of PHTP. Nowadays many patients with PHTP are discovered in their 
asymptomatic phase, especially in Western Europe and North Amerika(2) probably 
by routine screening  This project was aimed to characterize changes in muscle and 
hematopoietic gene expression in patients with reversible mild PHPT during illness 
and after parathyroidectomy and possibly link molecular pathology to the symptoms. 
The transcriptional activity was analysed in biopsies obtained before and one year 
after parathyroidectomy in 7 patients with mild PHTP  comparing bone marrow and 
muscle genes. My  task was to quantify the distribution of PTH receptors (PTHR1 and 
PTHR2) using real time RT-PCR in unrelated persons to define PTH target tissues 
and quantify PTH receptors in prathyroidectomized patients. These studies showed 
that PTHR1 and PTHR2 were more abundantly expressed in muscle and brain than in 
hematopoietic cells. It is possible that sustained stimulation of PTH receptors in 
brain,muscle, heart and hematopoietic cells because of elevated serum levels of PTH   
lead to alterations in gene expression and gives rise to symptoms like muscle fatigue, 





PHPT is one of the most common endocrine disorders and is usually caused by benign 
tumor in one of the parathyroid gland(parathyroid adenoma). Hyperplasia is present 
10%-20% of cases of primary hyperparathyroidism. This enlargement can occur of all 
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four parathyroid glands and in some cases enlargement may be grossly apparent in 
only one or two gland. More rare is conditions with two parathyroid adenomas while 
having two normal gland. PHPT  is more common in adults then in young people and 
more common in women than in men. 
 Many reports (2,14,23,24,42,43) emphasize the change in the clinical presenting 
picture form renal, bone related and gastrointestinal manifestations to psychological 
and psychiatric disorders as feelings of muscular weakness, apathy, cardiovascular 
manifestations  and ill defined mental symptoms. An increased cardiovascular 
morbidity has been reported even in mild disease(2), leading to over-presentation of 
cardiac death in patients with symptomatic PHTP both before and after 
parathyroidectomy suggesting development of non-reversible changes. 
 A study shows that adolescents and young adults have a clinical profile that differs 
from older patients(29). PHPT is rare condition in this age group. The report showed a 
non-specific symptomatology in adolescent and young  adult patients with primary 
hyperparathyroidism. Fatigue, exhaustion, weakness and lethargy were the most 
common  symptoms. Other symptoms were constipation, nephrolithiasis, polydipsia?, 
bone pain, palpitations, joint pain, polyuria or nocturia, pruritis, hypertension, 
depression and many other symptoms. It seems that a variety of symptoms and other 
organ manifestations are associated with PHTP.  
Nowadays many patients with PHTP are discovered in their asymptomatic phase, 
especially in Western Europe and North Amerika(2) by screening for PTH and Ca2+  
Very little is known about the molecular pathology/mechanisms associated with a 
chronic excessive action of PTH in different target tissues occurring during PHTP. 
The aim of the whole study was to describe changes in gene expression studied in 
bone marrow and skeletal muscle from patients with well defined and characterized, 
early PHPT before and after surgery when normalization of bone and biochemical 
markers had occurred. Each patient was used as their own control to describe 
molecular pathology expressed as mRNA profiles and suggest that the results may 
have clinical consequences reflecting chronic PTH receptor stimulation. My task was 
to quantify PTHR1 and PTHR2 in these patients using real time RT-PCR before and 
one year after surgery and  at the same time to quantify the distribution of  PTH-
receptors also using real time RT-PCR in unrelated persons to define PTH-receptor 





Patients and biopsies 
Seven arbitrarily chosen patients from 53.6 to 75.1 years of age (mean 60.3 years) 
without signs of organ affection, but with clinical biochemical evidence of mild PHPT 
were included.The diagnosis was established by elevated plasma PTH and  ionized 
calcium, taking care to rule out accessory conditions known to affect the PTH/calcium 
balance. The patients were screened for interfering conditions such as cardiovascular 
and renal disorders, endocrine disorders and other bone pathology. Vitamin D-status 
(25(OH)D and 1,25(OH)2D) was evaluated before iclusion. The patients had normal 
serum creatinine levels. The patients underwent successful parathyroidectomy. 
Biopsies containing bone, bone marrow and skeletal muscle tissue were taken before 
and one year after surgery from opposite, but symmetrical places of os ileum to avoid 
woven bone from first biopsy, immediately frozen in liquid nitrogen and stored at –
70C for RNA extraction. I quatified PTH receptors in these patients before and after 
surgery by using real time RT-PCR, this is a relative quantification compared to b-
aktin. Distribution of PTHR1 and PTHR2  in (normal) muscle, heart and other tissues 
I studied on biopsies from other patients taken during surgery. The receptors in CNS 
were analysed in post mortem tissue from non-demented humans. The study was 
performed according to Title 45, U.S. Code of Federal Regulations, Part 46, 
Protection of Human Subjects, and to the declaration of Helsinki II and approved by 
the Local Ethical Committee ( Ethics ref no:19980012) Informed written consent was 
obtained from each PHPT participant and healthy persons before entry. Also 
examination of post mortem specimen fulfilled all formal requirements. Purification 




Purification of  heart-RNA 
I used heart-biopsies of children with di-George syndrom. RNA was purified with the 
aid of TRIZOL (Life Techologies, Gaithersburg, MD). Here is the procedure: 
Reagents required ; 
Chloroform 
Isopropyl alcohol 
75% Ethanol (in DEPC-treated water) 
1.Homogenization of heart tissue: 
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Homogenize tissue samples in 1ml of TRIzol. The sample volume did/must not 
exceed 10% of the volume of TRIzol 
2. Phase seperation 
Incubate the homogenized samples for 5 min. at 30 C(degrees of Celsius), this is to 
permit the complete dissociation of nucleoprotein complexes. Add 0,2ml chloroform 
per 1 ml of TRIzol Reagent. Cap sample tubes securely. Shake tubes vigorously by 
hand for 15 sec. and incubate them at 30 C (degrees of Celsius) for 2-3min. 
Centrifuge the samples at no more than 12,000 x g for 15min. at 2-8 C (degrees of 
Celsius).  Following centrifugation , the mixture separates into a lower red, phenol-
chloroform phase, an interphase and a colorless upper aqueous phase. RNA remains 
exclusively in the aqueous phase.  
3. RNA precipitation 
Transfer the aqueous phase to a fresh tube. Precipitate the RNA from the aqueous 
phase by mixing with isopropyl alcohol. Use 0,5ml of isopropyl alcohol per 1 ml of 
TRIzol. Incubate samples at 30 C ( degrees of Celsius)  for 10 min. and centrifuge at 
12,000 x g for 10 min. at 2-8 C (degrees of Celsius). The RNA-precipitate, often 
invisible before centrifugation forms  a gel-like pellet on the side and bottom of the 
tube.  
4.RNA-wash 
Remove the supernatant. Wash the RNA pellet once with 75% ethanol, adding at least 
1 ml of 75% ethanol per 1 ml of TRIzol. Reagent used for the initial homogenisation. 
Mix the sample by vortexing and centrifuge at 7,500 x g for 5 min. at 2-8 C (degrees 
of Celsius) 
5. Redissolving the RNA 
At the end of the procedure, briefly dry the RNA pellet (air-dry for 5-10min). 
Dissolve RNA in RNase free water or 0,5% SDS solution (I used RNase free water) 
by passing the solution few times through a pipette tip, and incubating for 10 min. at 
55-60 C (degrees of Celsius).  
  
 
Preparation of CDNA 
I used RNA from previous heart tissue  to make CDNA by help from the enzyme 
reverse transkriptase? Equipment from Affymetrix was used. This was done in 2 
major steps: 
1.RNA/ T7-oligo(dT) Primer mix preparation 
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                                                Sample 1 
Heart RNA                              10 ul 
T7-oligo(dT)primer 50uM       2ul 
RNase free water                     0ul 
Total volume:                          12ul 
Mix the samples gently and vortex for 5 sec. Incubate at 70 C (degrees of Celsius) for 
10min. Cool down the samples at 4 C (degrees of Celsius) for at least 2 min. Vortex 
again for 5 sec. 
2. First-Strand Master Mix preparation. Here is the amount of the mix for one sample 
                                                     Master Mix 
5x1st Strand Reaction Mix                4ul 
DTT, 0,1M                                        2ul 
DNTP, 10mM                                   1 ul 
Total volum:                                      7ul 
Vortex the Master Mix gently for 5 sec. 7ul of First Strand Master Mix is taken in 
each sample. Afterwards vortex the samples for 5 sec. Incubate at 42 C ( degrees of 
Celsius) for 2 min. Add 1 ul Super Script II(reverse transkriptase) to each sample. 
Mix gently and vortex for 5 sec.  Incubate the samples at 42 C ( degrees of Celsius) 
for 1 hour. Cool down the samples at 4 C (degrees of Celsius) at least for 2 min. 
Centrifugate at for 5 sec just so that the fluid collets at the end of the tube.  
In the same matter I did CDNA preparation from RNA from some samples of 
bonemarrow, muscle and different brain sections.  
 
Real time RT-PCR 
The distribution of PTHR1 and PTHR2 were analysed by real time RT-PCR 
employing the Light Cycler and the Fast Start Master SYBR Green kit 
(cat.no.2239264, Roche Diagnostics) according to manufacturers instructions. One 
sample from each organ/region from three different persons was analysed in 
triplicates. Cycling profile: 94 C (degrees of Celsius) for 5 min, then 40 cycles of    
(60 C for 30sec., 72 C for 30 sec., and 95 C fro 30 sec) and 3 min 72 C. Gene 
expression was normalized/compared  to b-actin. The mRNA levels were tested in 
triplicates from 3 different persons  The final results are presented in the figure 2 with 
bars illustrating mean+-SD 
Gene expression was normalized to β-actin.  Primers:  
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β-actin: Forw. GCTACAGCTTCACCACCACA     Rev. 
GCCATCTCTTGCTCGAAGTC 
PTHR1: Forw. GTCCCTGAGACCTCGGTGTA     Rev. 
AGTACCGGAAGGTGCTCAAA 































                         TABLE 1 and FIGURE 2 
 
 
 Human PTH-receptor 1 and 2 expression is analysed by Real time PCR. 2µl of total 
RNA was analysed. 
The data is given in ratio(N) to the expression level to b-actin that is set to be 1. The 
data is calculated out of crossing points(CT) of the different receptors.  



















































17,57±0,17 14,23  19215 10,88 1885 0,00005 0,00053 



















































                                   Quantification of PTH receptors in patients with PHPT  















31,22±0,095 19,96±0,140 8,38 11,26 
4 29,43±0,115 31,35±0,181 20,11±0,045 9,32 11,24 














1 30,55±0,0077 30,62±0,06 19,71±0,053 10,84 10,91 
2 29,72±0,064 30,83±0,018 20,62±0,223 9,1 10,21 
4 30,45±0,099 31,31±0,230 20,29±0,224 10,16 11,02 




                                    Discussion 
 
Three types of PTH receptors (PTH/PTHrp receptor(PTHR1), the N-terminal PTH 
receptor 2 (PTHR2), and the C-PTH receptor(22,38,46,47)) have been isolated or 
partly characterized. Real time RT-PCR of PTHR1 mRNA showed a 2.0 ±0.9 fold 
increase in PHPT  while PTHR2 mRNA expression was un-altered, confirming the 
Affymetrix data (35). These results show that. PTHR1 and PTHR2 mRNAs were both 
present in all human tissues and cells tested except for the small intestine where only 
PTHR1 mRNA was detected (Fig. 2). The abundant and uniform representation of the 
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two receptors mRNA in the CNS, especially Cerebellum, Amygdala, Hippocampus, 
Superior Frontal Gyrus, Superior Parietal Gyrus, Thalamus and Hypothalamus is 
noteworthy, reaching almost the level of actin (Fig. 2). This can be of great 
importance in explaining  the different psychiatric manifestations in PHPT. Cardiac 
and skeletal muscle contains on average about 1/10 of the mRNA amounts present in 
the most enriched regions of the brain. All of the patients had high serum PTH while 
showing small or modest rises in serum Ca2+. Since the median change in serum PTH 
and Ca2+ during disease was 5-fold and 1.25-fold respectively,it is tempting to regard 
PTH and not serum Ca2+, as a major cause of the molecular de arrangement.  In this 
way PTH action on the receptors in cardiac and skeletal muscle could be responsible 
for heart hypertrophy and muscular fatigue,myopathy  and other symptoms rising 
from these structures. 
The present study indicates that chronic PTH stimulation affects defined groups of 
mRNAs expressed in all target cells. It is therefore important to define the human 
target cells/tissues for PTH in order to understand the observed molecular changes in 
relation to clinical cell and organ pathology
Our study showed through Affymetrix profound changes observed in specific 
molecular patterns, and different molecular pathology  For example the 
canonical pathways were affected, most significantly “Calcium 
Signaling”pathway  in which 50 out of 172 mRNAs showed changed expression 
during disease This pathway is important in the contractile process of a muscle   
At the same time it probably involves also the cardiac β-adrenergic system 
present in cardiomyocytes.  This could help explain the dys-regulation of 
cardiac function and development of left ventricular hypertrophy and failure 
representing the main cause of premature death in patients with PHPT (20, 36) 
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Expression of genes that regulate proliferation and differentiation of muscle 
related cells were altered in patients with PHPT 
Affymeterix also showed us that different genes affecting the innate immune 
system were affected in patient with PHPT  Expression of chemokine, 
complentent components and other genes were altered  
This could be related to resistance to infections and increased prevalence 
and premature death of malignant diseases in PHPT (1, 3, 11, 13, 20, 32). A 
relationship between PHPT and infection is described being the 4th most 
prevalent cause of premature death (20). Also, high prevalence of H. pylori in 
patients with PHPT (11) and urinary tract infections in 26 % of 201 tested dogs 
with PHPT (13) point to an increased susceptibility to infections.  
Our study suggests that there may be many different molecular mechanisms that may 
explain clinical consequences of PHPT,but that these are mediated by the excess PTH 
and its action on PTH receptors  Patient with PHPT showed a great increase in 
PTHR1 mRNA, while the PTHR2 mRNA was unaltered during disease. The present 
results points to that early diagnosis and treatment of these patients may avoid 
irreversible molecular pathology. At the same time these results can give rise to 
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